Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: A multicenter, open-label, uncontrolled study over three treatment cycles

Contraception

Volumn 90, Issue 3, 2014, Pages 272-279

  Westhoff, Carolyn L ^a   Reinecke, Isabel ^b   Bangerter, Keith ^b   Merz, Martin ^b  

^a NewYork Presbyterian Hospital   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

BMI; Contraceptive patch; Hoogland score; Ovulation inhibition; Pharmacokinetic

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE; SEX HORMONE BINDING GLOBULIN; CONTRACEPTIVE AGENT; DRUG COMBINATION; ETHINYLESTRADIOL; GESTODENE; PREGNANE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTRACEPTIVE PATCH; DRUG BLOOD LEVEL; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OVARY FOLLICLE DEVELOPMENT; OVULATION INHIBITION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROGESTERONE BLOOD LEVEL; TRANSDERMAL PATCH; TRANSVAGINAL ECHOGRAPHY; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; ECHOGRAPHY; FOLLICULAR PHASE; FOLLOW UP; OBESITY; OOCYTE DEVELOPMENT; OVARY FOLLICLE; PATHOPHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; BODY MASS INDEX; CONTRACEPTIVE AGENTS, FEMALE; DRUG COMBINATIONS; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; FOLLICULAR PHASE; FOLLOW-UP STUDIES; HUMANS; LOST TO FOLLOW-UP; NORPREGNENES; OBESITY; OOGENESIS; OVARIAN FOLLICLE; OVERWEIGHT; OVULATION INHIBITION; PROGESTERONE; SEX HORMONE-BINDING GLOBULIN; TRANSDERMAL PATCH; YOUNG ADULT;

EID: 84907597262     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2014.04.018     Document Type: Article

References (27)

1. Evra transdermal patch Summary of product characteristics 2012 Janssen-Cilag Belgium
2. H. Kuhl Pharmacology of estrogens and progestogens: influence of different routes of administration Climacteric 8 Suppl. 1 2005 3 63
3. D. Heger-Mahn, C. Warlimont, T. Faustmann, C. Gerlinger, and C. Klipping Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers Eur J Contracept Reprod Health Care 9 2004 173 181
4. M.I. Wilde, and J.A. Balfour Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations Drugs 50 1995 364 395
5. B. Kaplan Desogestrel, norgestimate, and gestodene: the newer progestins Ann Pharmacother 29 1995 736 742
6. I.C. Barbosa, C.I. Filho, D. Faggion Jr., and E.C. Baracat Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse) Contraception 73 2006 30 33
7. G. Benagiano, F.M. Primiero, and M. Farris Clinical profile of contraceptive progestins Eur J Contracept Reprod Health Care 9 2004 182 193
8. M.C. Audet, M. Moreau, W.D. Koltun, A.S. Waldbaum, G. Shangold, and A.C. Fisher et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial JAMA 285 2001 2347 2354
9. R. Dittrich, L. Parker, J.B. Rosen, G. Shangold, G.W. Creasy, and A.C. Fisher Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study Am J Obstet Gynecol 186 2002 15 20
10. G.H. Smallwood, M.L. Meador, J.P. Lenihan, G.A. Shangold, A.C. Fisher, and G.W. Creasy Efficacy and safety of a transdermal contraceptive system Obstet Gynecol 98 2001 799 805
11. W. Urdl, D. Apter, A. Alperstein, P. Koll, S. Schonian, and J. Bringer et al. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception Eur J Obstet Gynecol Reprod Biol 121 2005 202 210
12. R.A. Pierson, D.F. Archer, M. Moreau, G.A. Shangold, A.C. Fisher, and G.W. Creasy Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error Fertil Steril 80 2003 34 42
13. M. Zieman, J. Guillebaud, E. Weisberg, G.A. Shangold, A.C. Fisher, and G.W. Creasy Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data Fertil Steril 77 2 Suppl. 2 2002 S13 S18
14. C.L. Ogden, M.D. Carroll, B.K. Kit, and K.M. Flegal Prevalence of obesity in the United States, 2009-2010 NCHS Data Brief 82 2012 1 8
15. World Health Organization Sexual and reproductive health: medical eligibility criteria for contraceptive use 4th ed. 2009 [Available at: http://whqlibdoc.who.int/publications/2010/9789241563888-eng.pdf. Last accessed: 1st Aug 2013]
16. H.J. Hoogland, and S.O. Skouby Ultrasound evaluation of ovarian activity under oral contraceptives Contraception 47 1993 583 590
17. S.L. Beal, and L.B. Sheiner Estimating population kinetics Crit Rev Biomed Eng 8 1982 195 222
18. V.L. Holt, K.L. Cushing-Haugen, and J.R. Daling Body weight and risk of oral contraceptive failure Obstet Gynecol 99 2002 820 827
19. V.L. Holt, D. Scholes, K.G. Wicklund, K.L. Cushing-Haugen, and J.R. Daling Body mass index, weight, and oral contraceptive failure risk Obstet Gynecol 105 2005 46 52
20. J. Trussell, E.B. Schwarz, and K. Guthrie Obesity and oral contraceptive pill failure Contraception 79 2009 334 338
21. J.C. Dinger, M. Cronin, S. Mohner, I. Schellschmidt, T.D. Minh, and C. Westhoff Oral contraceptive effectiveness according to body mass index, weight, age, and other factors Am J Obstet Gynecol 201 2009 263.e1 263.e9
22. C.L. Westhoff, A.H. Torgal, E.R. Mayeda, F.Z. Stanczyk, J.P. Lerner, and E.K. Benn et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial Obstet Gynecol 116 2010 275 283
23. C.L. Westhoff, A.H. Torgal, E.R. Mayeda, K. Petrie, T. Thomas, and M. Dragoman et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women Am J Obstet Gynecol 207 2012 39.e1 39.e6
24. A.B. Edelman, N.E. Carlson, G. Cherala, M.Y. Munar, R.L. Stouffer, and J.L. Cameron et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity Contraception 80 2009 119 127
25. A.B. Edelman, G. Cherala, M.Y. Munar, B. Dubois, M. McInnis, and F.Z. Stanczyk et al. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users Contraception 87 2013 220 226
26. C.L. Westhoff, A.T. Torgal, E.R. Mayeda, N. Shimoni, F.Z. Stanczyk, and M.C. Pike Predictors of noncompliance in an oral contraceptive clinical trial Contraception 85 2011 465 469
27. L.B. Finer, and M.R. Zolna Unintended pregnancy in the United States: incidence and disparities, 2006 Contraception 84 2011 478 485